Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Analysts Skeptical About Ability Of Korean Government To Draw Investors To Risky R&D Fund

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Investors and analysts are voicing skepticism about the Korean government's ability to successfully draw enough investors into a KRW2 trillion ($1.7 billion) R&D fund to help local companies develop innovative new drugs

You may also be interested in...



Korean Health Minister Could Enlist Special Prosecutor To Fight Kickbacks By Drug Makers

SEOUL - South Korea's Minister of Health, Welfare and Family Affairs Jeon Jae-hee has issued a warning that the ministry might enlist a special state prosecutor to fight the widespread practice of pharmaceutical companies giving kickbacks to doctors

New Pricing System Could Deal A Blow To South Korea's Generic-Dependent Companies

SEOUL - As part of its effort to root out illegal rebates, the Ministry for Health, Welfare and Family Affairs said it would launch a new "drug-pricing system" in October aimed at compensating hospitals that buy drugs at lower prices than their government-set maximum prices

Korean Government Announces Joint Fund To Beef Up Local Pharma Industry

SEOUL - The Korean government is moving to create a KRW2 trillion ($1.7 billion) research and development fund to help local Korean pharma companies develop globally competitive new drugs

Latest Headlines
See All
UsernamePublicRestriction

Register

SC074106

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel